Perth, Australia,, February 4, 2025 / Prnewswire / – This partnership allows Neopharma to introduce a revolutionary solution that combines drug tests with depreciation tests to fill a crucial gap on the market. With the continuous expansion of the legalization of marijuana across the United States and in the world, the need for tools for assessing precise and reliable disabilities has never been greater. Directly finding the growing challenges faced by employers and industries sensitive to security, this integrated solution allows organizations to carry out, interpret and report thousands of results from drug testing and cognitive disorders assessments .
Combined data, accessible via the Neovault® application in Neopharma, is now available on Apple App Store and Google Play. It allows employers in real time information, considerably improving decision -making in the increasingly complex legal cannabis landscape.
CEO of deficiency sciences Rob Schillerexpressing his enthusiasm for the partnership, said, “We are absolutely delighted to work more closely with Neopharma technologies. Indeed, we hope to deepen the relationship with greater collaboration and integration over time. Whereas a new era in safety and productivity under -employed. “”
Nina M. FrenchCEO of Neopharma Technologies, stressing the importance of this innovation, said, “This marks an important progression for employers in the United States and, finally, worldwide, while we take advantage of advanced technologies to measure and face drug disability. Partnership with the science of deficiency We provides a revolutionary solution in 2025 to workplaces.
This combination addresses a long -standing question which has only become complex since the medical legalization of cannabis in 1996 and the recreational legalization in progress since 2012. This strategic alliance highlights both neopharmatic technologies and the commitment of science From impairment to innovation, security and provision of usable information to our partners, stimulate value and leadership on a critical market. “”
On Neopharma technologies
Neopharma Technologies LTD., dedicated to the development of advanced solutions that meet the pressing needs of the industry, has created the next generation of drug tests. Our commitment to advance technology and improve efficiency stimulates our mission to provide exceptional products and services.
On the science of disorders
The science of deficiencies specializes in cognitive impairment technologies, providing solutions, including druid, its adjusted application, which improves labor safety and productivity. Our innovative approach, using neuroscience, provides rapid, precise and objective assessments of cognitive function, supporting a safer and less expensive work environment.
Contact: Shaun Melville,, shaun@neopharmatechnologies.com
Show the original content:https://www.prnewswire.com/apac/news-releases/neopharma-technologies-nda-impairment-science-strenghen-startnership-to-revolutionize-drug-and-impaurment-testing-302367247.html
Source of Neopharma technologies
